Cargando…
AZGP1P2/UBA1/RBM15 Cascade Mediates the Fate Determinations of Prostate Cancer Stem Cells and Promotes Therapeutic Effect of Docetaxel in Castration-Resistant Prostate Cancer via TPM1 m6A Modification
Prostate cancer (PCa) is a common malignant tumor with high morbidity and mortality worldwide. The prostate cancer stem cell (PCSC) model provides novel insights into the pathogenesis of PCa and its therapeutic response. However, the roles and molecular mechanisms of specific genes in mediating fate...
Autores principales: | Wang, Hong, Liu, Ji, Zhu, Xiaojun, Yang, Bin, He, Zuping, Yao, Xudong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AAAS
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581371/ https://www.ncbi.nlm.nih.gov/pubmed/37854295 http://dx.doi.org/10.34133/research.0252 |
Ejemplares similares
-
Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells
por: Cánovas, Verónica, et al.
Publicado: (2017) -
AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy
por: Winther, Mads Dochedahl, et al.
Publicado: (2020) -
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015) -
Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021) -
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)